YIM Agenda staging -8-27-21

Monday 13 September 2021

 
8:00 AM (EDT)
14:00 (CEST)
10 mins Welcome and Introductions Welcome & Opening Remarks by Tadeusz Robak, MD, PhD;
Petra Langerbeins, MD; Bartosz Pula. MD, PhD
8:10 AM (EDT)
14:10 (CEST)
  Session 1: Pathogenesis of CLL Chairs: Dimitar Efremov, MD, PhD; Marek Mraz, PhD; & Elisa ten Hacken, PhD
8:10 AM (EDT)
14:10 (CEST)
10 mins Small Extracellular Vesicles Derived from CLL Microenvironment Sustain Disease Progression padding-right: 30px;in Vivo by Hampering Anti-tumor Immunity
(1084065)
Ernesto Gargiulo, MSc
8:20 AM (EDT)
14:20 (CEST)
10 mins GAB1 – Novel Regulator of Migration Capacity and Tonic AKT Activity in CLL:
Implications for Combinatorial Therapy with BCR Inhibitors
(1084081)
Vaclav Seda, MSc
8:30 AM (EDT)
14:30 (CEST)
10 mins Effects of SF3B1 K700E mutation in chronic lymphocytic leukemia and the
opportunity for targeted therapy with SF3B1-binding splicing modulator H3B-8800
(1084295)
Irene Lopez-Oreja, PhD
8:40 AM (EDT)
14:40 (CEST)
10 mins Role of Ahr and Hif1a in the Suppressive Ability of Tregs During CLL Development
(1083804)
Giulia Maria Pagano, MSc
8:50 AM (EDT)
14:50 (CEST)
10 mins RPS15 mutation impacts B cell fate and drives B cell malignancy
through Myc activation in a murine model
(1084599)
Catherine Gutierrez, PhD
9:00 AM (EDT)
15:00 (CEST)
20 mins

Recap, Q&A

 
9:20 AM (EDT)
15:20 (CEST)
5 mins Break  
9:25 AM (EDT)
15:25 (CEST)
  Session 2: Approach Considerations and Treatment Options in CLL Chairs: Inhye Ahn, MD; Anthony Mato, MD, MSCE; 
& Talha Munir, MD
9:25 AM (EDT)
15:25 (CEST)
10 mins Cell-free DNA (cfDNA)-based Serial Minimal Residual Disease Assessment
in Patients with Chronic Lymphocytic Leukemia Treated with Time-limited Obinutuzumab, Acalabrutinib and Venetoclax
(1084129)
Moritz Fürstenau, MD
9:35 AM (EDT)
15:35 (CEST)
10 mins Comparison of Clinical and Laboratory Features, Drug Availability, and
Outcomes of CLL Patients Treated in Public or in Private Hospitals in Brazil:
A Retrospective Analysis of the Brazilian Registry of CLL
(1083568)
Verena Pfister
9:45 AM (EDT)
15:45 (CEST)
10 mins VENETOCLAX Ramp-Up Strategies For CLL. UK Real World Multicentre
Retrospective Study
(1084425)
Rocío Figueroa
9:55 AM (EDT)
15:55 (CEST)
10 mins Utilizing Clinical Features of Progression to Predict Richter’s Syndrome in Patients with CLL Progressing After Ibrutinib
(1084068)
Adam S. Kittai, MD
10:05 AM (EDT)
16:05 (CEST)
10 mins Evaluation of Immunoglobulin Gene Somatic Hypermutation Status by Next Generation Sequencing Is Superior to Using Sanger Sequencing
(1084095)
Mengge Gao, MD
10:15 AM (EDT)
16:15 (CEST)
20 mins

Recap, Q&A

 
10:35 AM (EDT)
16:35 (CEST)
5 mins Break  
10:40 AM (EDT)
16:40 (CEST)
  Session 3: Rationally Designed Therapy on the Horizon in CLL Chairs: Florence Cymbalista, MD, PhD; Petra Langerbeins, MD; & Bartosz Pula, MD
10:40 AM (EDT)
16:40 (CEST)
10 mins Venetoclax resistance mechanisms in CLL identified by whole exome and RNA sequencing on longitudinal patient samples
(1084402)
Ishwarya Murali
10:50 AM (EDT)
16:50 (CEST)
10 mins CD19 promoter hypermethylation as means of antigen-negative escape
to CART-19 therapy
(1084273)
Lenka Dostalova
11:00 AM (EDT)
17:00 (CEST)
10 mins A Phase I Trial of Nedd8-Activating Enzyme (NAE) Inhibitor, Pevonedistat (PEVO) in Combination with Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL)
(1082565)
Pallawi Torka, MD
11:10 AM (EDT)
17:10 (CEST)
10 mins BTK inhibitors, irrespective of ITK inhibition, downregulate an immunosuppressive program in chronic lymphocytic leukemia and enhance
CD19/CD3-mediated cytotoxicity of T cells
(1084197)
Maissa Mhibik, PhD
11:10 AM (EDT)
17:10 (CEST)
10 mins Longitudinal antibody Levels and T- cell Response Following BNT162b mRNA Covid19 Vaccine in Patients with Chronic Lymphocytic Leukemia on Behalf of the Israeli CLL Study Group
(1083588)
Tamar Tadmor, MD
11:20 AM (EDT)
17:20 (CEST)
20 mins

Recap, Q&A

 
11:30 AM (EDT)
17:30 (CEST)
10 mins Break  
    Concurrent Bootcamp Sessions  
    Basic Biology Investigator Bootcamp
Poster Presentations From the Podium and Roundtable Discussion
(7 min presentation; 3 min discussion)
Chairs: Shih-Shih Chen, PhD; Davide Rossi, MD, PhD; Freda Stevenson & Elisa TenHacken, PhD
12:00 PM (EDT)
18:00 (CEST)
50 mins Establishment and Molecular Characterization of a 3D Bioprinted
Chronic Lymphocytic Leukemia (CLL) in Vitro Model
(1083882)
Riccardo Pinos, MSc
Ibrutinib Blocks CD40 Signaling in CLL in Vivo by Reducing TRAF4 Levels
(1084082)
Sonali Sharma, PhD
Single-cell RNA Sequencing Suggests Novel Drivers of Chronic Lymphocytic Leukemia in Patients with Ibrutinib Resistance
(1084066)
Hui Jin, MD
Ebi3/IL-27 Depleted Microenvironment Favours Tumour Progression in Chronic Lymphocytic Leukaemia
(1082745)
Iria Carmen Fernandez Botana, MSc
Unraveling Functional Consequences of AID Off-target Mutations in CLL
(1083548)
Amparo Rico
12:50 PM (EDT)
18:50 (CEST)
20 mins Career Development Discussion Davide Rossi,
Freda Stevenson
1:10 PM (EDT)
19:10 (CEST)
5 mins Break  
    Translational Investigator Bootcamp
(Poster Presentations From the Podium and Roundtable Discussion
(7 min presentation; 3 min discussion)
Chairs: Chaja Jacobs, MD;
Arnon Kater,
MD, PhD; &
Adrian Wiestner, MD, PhD
12:00 PM (EDT)
18:00 (CEST)
50 mins Inhibition of the Pentose-phosphate-pathway (PPP) Mediates Macrophage Reprogramming and Induces Increased Antibody-dependent Lymphoma Cell Clearance by Macrophages While Supportive Bystander Function Is Diminished
(1084060)
Anna Beielstein
Single-cell Dynamics of Mitochondrial DNA Mutations and Chromatin
Accessibility in Chronic Lymphocytic Leukemia Following Therapeutic Bottlenecks
(1084075)
Livius Penter, MD
IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3K Inhibitor Idelalisib
(1084080)
Veronika Palusova, PhD
Pharmacologic Inhibition of SUMO-activating Enzyme Potentiates Interferon
Response and T Cell-mediated Anti-tumor Immunity in Chronic Lymphocytic
Leukemia (CLL) and Lymphoma Models
(1083519)
Vi Lam, BS
Targeting Translation by Disrupting the Newly Identified Prohibitin-eIF4F Complex as a Novel Therapeutic Strategy in CLL
(1084070)
Anne Largeot, PhD
12:50 PM (EDT)
18:50 (CEST)
20 mins Career Development Discussion  
1:10 PM (EDT)
19:10 (CEST)
5 mins Break  
    Clinical Investigator Bootcamp
(Poster Presentations From the Podium and Roundtable Discussion
(7 min presentation; 3 min discussion)
Chairs: Matthew Davids, MD, MMSc; Talha Munir, MD; &
Jennifer Woyach, MD
12:00 PM (EDT)
18:00 (CEST)
50 mins Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Sequentially
Resistant to Both BCL2 and BTK Inhibition
(1083790)
Victor S. Lin, MD
BCL3 Gene Rearrangement at IgH Locus, t(14;19), Identifies an Aggressive Subset of Chronic Lymphocytic Leukemia. an ERIC and Italian Campus CLL Study
(1083625)
Panagiotis Baliakas, MD PhD
Treatment in the First 24 Months from Diagnosis Predicts Shorter Survival
in Binet a Stage Patients with Chronic Lymphocytic Leukemia. a CLL Campus Study
(1083334)
Gianluigi Reda, MD
Optical Genome Mapping: a new promising tool to assess genomic complexity in chronic lymphocytic leukemia (CLL)
(1084272)
Anna Puiggros, PhD
Healthcare Team Burden Due To the Utilization of Novel Therapeutics for Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies
(1084593)
Maishara Muquith, B.A.
12:50 PM (EDT)
18:50 (CEST)
20 mins Career Development Discussion

Matthew Davids, MD, Talha Munir, MD; & Jennifer Woyach, MD

1:10 PM (EDT)
19:10 (CEST)
5 mins Break  
    Bootcamp Recap and YIM Award Presentation  
1:15 PM (EDT)
19:15 (CEST)
30 mins Recap of Previous Bootcamp Sessions

TBD

1:45 PM (EDT)
19:45 (CEST)
15 mins YIM Award and Concluding Remarks

Awards – Petra Langerbeins, MD; Bartosz Pula, MD, PhD

Concluding Remarks – Tadeusz Robak, MD, PhD

2:00 PM (EDT)
20:00 (CEST)
  Adjourn